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19th CardioVascular Summit: TCTAP 2014Bifurcation and Left Main Stenting
(TCTAP A-004 to TCTAP A-005)
TCTAP A-004
Optimal Strategy for Bifurcation Lesions: CROSS and PERFECT Trials
Young-Hak Kim, Seung-Jung Park
Asan Medical Center, Seoul, Korea (Republic of)
Background: In spite of many clinical studies, bifurcation coronary lesions still
remain a lesion subset demanding complex procedure and relatively high complication
rate with percutaneous coronary intervention.
Methods: Two parallel randomized studies were performed to compare the two
stenting techniques, which have been most popularly used for bifurcation coronary
lesions with diseased and non-diseased SB. The Choice Of Optimal Strategy For
Bifurcation Lesions With Normal Side Branch (CROSS) study evaluated the role of
routine ﬁnal kissing balloon (FKB) inﬂation as compared with selected use of FKB for
bifurcation lesions with non-diseased SB. Another randomized study of Optimal
Stenting Strategy For True Bifurcation Lesions (PERFECT) study compared the crush
technique and provisional T-stenting technique for bifurcations with diseased SB. The
two studies were designed with two separate protocols, however, has been performed
in the same study period to consecutively enroll all potential candidates of bifurcation
lesions. The CROSS and PERFECT trials were a prospective, open-label, randomized
studies. Patients were eligible for the study if they were 18w75 years old and had
angina with bifurcation coronary disease requires protection in which the main branch
had reference diameter  2.5 mm and lesion length  50 mm and the side branch
(SB) has reference diameter  2.0 mm. Exclusion criteria were unprotected left main
disease, in-stent restenosis, graft lesions, chronic total occlusion, ST-elevation
myocardial infarction within 2 weeks, decreased SB ﬂow, renal failure, low left
ventricular ejection fraction  35%, and serious comorbidities with life expectancy <
1 year. If patients met the inclusion and exclusion criteria, SB stenosis by visual
estimation determine the inclusion of CROSS for SB with stenosis < 50% and
PERFECT study for SB with stenosis  50% and length < 20mm, respectively.
Results: The ﬁnal angiographic and clinical results will be presented at TCTAP 2014.
Conclusion: The CROSS and PERFECT study will be helpful to understand the
outcomes of different stenting techniques and select optimal stenting technique for
patients with bifurcation coronary lesions.S2 JACC Vol 63/12/Suppl S j April 22–2TCTAP A-005
Randomized Comparison of Coronary Bypass Surgery with Drug-Eluting
Stenting for the Treatment of Left Main Coronary Artery Disease: 3-Year
Follow-Up of the PRECOMBAT Trial
Jung-Min Ahn, Young-Hak Kim, Jong-Young Lee, Soo-Jin Kang, Duk-Woo Park,
Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Asan Medical Center, Seoul, Korea (Republic of)
Background: Long-term randomized comparisons of percutaneous coronary inter-
vention (PCI) to coronary artery bypass grafting (CABG) in patients with left main
coronary (LM) disease have been limited. We compared 3-year outcomes in patients
with LM disease treated with CABG or PCI with sirolimus-eluting stents.
Methods: We randomly assigned patients with unprotected left main coronary artery
stenosis to undergo CABG (300 patients) or PCI with sirolimus-eluting stents (300
patients). We analyzed a composite rate of major adverse cardiac or cerebrovascular
events [MACCE: death from any causes, myocardial infarction (MI), stroke, or
ischemia-driven target-vessel revascularization (TVR)] at 3-year follow-up on an
intention-to-treat basis.
Results: At 3 years, MACCE (14.5% vs. 9.4%, P¼0.039) were elevated in the PCI
arm. However, rates of the composite safety endpoint (death/stroke/MI 6.1% vs. 6.0%,
P¼ 0.76) were not signiﬁcantly different between treatment groups. Individual
components of outcomes including death from any causes (3.7% vs. 4.4%, P¼0.82),
MI (1.4% vs. 1.0%, P¼0.48), and stroke (1.0% vs. 1.0%, P¼0.99) were not signiﬁ-
cantly different. Ischemia-driven TVR was signiﬁcantly higher in PCI arm (9.3% vs.
4.1%, P¼0.014).
Conclusion: At 3 years, the occurrence of the composite of death, MI, and stroke were
comparable between groups, but ischemia-driven TVR had been signiﬁcantly
increased in PCI- compared with CABG-treated patients since 1 year after the
treatment.5, 2014 j TCTAP Abstracts/LBCT/Bifurcation and Left Main Stenting
